Ester Neurosciences Ltd. is a development stage biopharmaceutical company committed to the discovery and development of novel therapeutic products for the treatment of neurological disorders such as myasthenia gravis, Alzheimer’s disease, multiple sclerosis and acute stress reactions. Ester’s unique platform technology is based on the company’s breakthrough discoveries relating to cholinergic neuromodulation and its involvement in the diseased state. Ester was led by Prof. Eli Hazum, and founded in 1997. [via]
- Israel’s Pre-seed 2024 Report and 2025 Sentiment - February 25, 2025
- Weekly Firgun Newsletter – February 21 2025 - February 21, 2025
- The AI Jobs Report: What’s at Risk and Where the Opportunity Lies - February 17, 2025